Significant Prevalence of Autoimmune Diseases is Reflecting Positively on the North American Biologics Market

North American biologics market is estimated to grow at a CAGR of 8.4% during the forecast period. As per the data published by the National Institutes of Health in 2017, nearly 23.5 million Americans (over 7% of the population) suffer from an autoimmune disease. The prevalence of the autoimmune disease is growing significantly coupled with rising incidences of arthritis in the region. The rising prevalence of autoimmune diseases is supporting the adoption of biologics in the region. Biologics may be prescribed for the treatment of autoimmune diseases, which include several kinds of arthritis, including psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.

Browse the full report description of "North American Biologics Market Size, Share & Trends Analysis Report, By Product (Antibody Therapeutics, Vaccines, Cell Therapy, Gene Therapy, and Others), By Application (Cancer, Autoimmune Diseases, Infectious Diseases, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/north-american-biologics-market 

Biologics drugs function by disrupting the inflammation process that results in joint pain and destruction. These are genetically engineered drugs that are intended to interact with the immune response to reduce the damaging effects of rheumatologic disorders. For rheumatoid arthritis, these drugs particularly target proteins that are involved in joint inflammation. In some rheumatoid arthritis patients, biologics can be provided alone or along with traditional drugs to support slowing down the progression of rheumatoid arthritis. 

Scope of the North American Biologics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Product and Application
• Countries Covered- US and Canada
• Competitive Landscape- AbbVie Inc., Amgen Inc., Pfizer Inc., F. Hoffman-La Roche AG, and Boehringer Ingelheim GmbH

Recent Strategic Initiatives in the North American Biologics Market

• In June 2020, EMD Serono, and Pfizer Inc. declared the approval of the US FDA supplemental Biologics License Application for BAVENCIO (avelumab). The drug is approved for the maintenance treatment of patients suffering from metastatic or locally advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. It is the first immunotherapy that has shown a statistically potential improvement in the whole survival in the first-line setting in urothelial carcinoma. Therefore, the approval of avelumab by the US FDA is one of the potential advances for the treatment of metastatic or locally advanced urothelial carcinoma in 30 years.
• In February 2019, Alder presented a Biologics License Application (BLA) to the US FDA for eptinezumab. During 2020, Lundbeck expects to present eptinezumab for European Union approval, followed by proposals for approval in other regions across the globe including Japan and China. This acquisition will accelerate Lundbeck’s late-stage pipeline and offering access to novel capabilities in the field of monoclonal antibody treatment.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID-19 forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Biologics Market-Segmentation

By Product

• Antibody Therapeutics
• Vaccines
• Cell Therapy
• Gene Therapy
• Others

By Application

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

North American Biologics Market– Segment by Country

• US
• Canada